By Ian Walker
AstraZeneca raised its full-year guidance for core earnings per share and total revenue excluding Covid-19 medicines despite a lower third-quarter profit that missed forecasts.
The Anglo-Swedish pharmaceutical giant said Thursday that it expects core earnings per share to increase by a low double-digit percentage compared with previous guidance of a high single-digit to low double-digit percentage increase.
Total revenue excluding Covid-19 medicines is now expected to increase by a low-teens percentage at constant exchange rates compared with previous expectations of low double-digit percentage growth.
Write to Ian Walker at ian.walker@wsj.com
